Wall Street brokerages expect that Integra LifeSciences Holdings Corporation (NASDAQ:IART) will announce $286.37 million in sales for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have issued estimates for Integra LifeSciences Holdings Corporation’s earnings, with the highest sales estimate coming in at $288.80 million and the lowest estimate coming in at $284.00 million. Integra LifeSciences Holdings Corporation posted sales of $250.33 million in the same quarter last year, which suggests a positive year over year growth rate of 14.4%. The firm is scheduled to announce its next earnings report on Thursday, October 26th.

On average, analysts expect that Integra LifeSciences Holdings Corporation will report full year sales of $286.37 million for the current financial year, with estimates ranging from $1.12 billion to $1.20 billion. For the next fiscal year, analysts expect that the firm will report sales of $1.29 billion per share, with estimates ranging from $1.19 billion to $1.55 billion. Zacks’ sales averages are an average based on a survey of analysts that that provide coverage for Integra LifeSciences Holdings Corporation.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last released its quarterly earnings data on Wednesday, July 26th. The life sciences company reported $0.45 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.45. The firm had revenue of $282.16 million during the quarter, compared to the consensus estimate of $283.58 million. Integra LifeSciences Holdings Corporation had a return on equity of 16.79% and a net margin of 6.27%. The company’s quarterly revenue was up 13.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.40 earnings per share.

IART has been the subject of a number of research analyst reports. Cantor Fitzgerald set a $65.00 target price on Integra LifeSciences Holdings Corporation and gave the company a “buy” rating in a research note on Wednesday, July 26th. Oppenheimer Holdings, Inc. restated a “buy” rating on shares of Integra LifeSciences Holdings Corporation in a research note on Wednesday, July 26th. UBS AG restated a “buy” rating and issued a $60.00 target price (up previously from $48.00) on shares of Integra LifeSciences Holdings Corporation in a research note on Friday, June 9th. Jefferies Group LLC raised their target price on Integra LifeSciences Holdings Corporation from $52.00 to $58.00 and gave the company a “buy” rating in a research note on Wednesday, May 31st. Finally, Barclays PLC restated an “equal weight” rating and issued a $53.00 target price (up previously from $47.00) on shares of Integra LifeSciences Holdings Corporation in a research note on Tuesday. Five investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. Integra LifeSciences Holdings Corporation presently has a consensus rating of “Buy” and a consensus target price of $53.54.

COPYRIGHT VIOLATION NOTICE: “$286.37 Million in Sales Expected for Integra LifeSciences Holdings Corporation (IART) This Quarter” was reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/09/16/286-37-million-in-sales-expected-for-integra-lifesciences-holdings-corporation-iart-this-quarter.html.

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) opened at 51.92 on Friday. The stock’s 50 day moving average price is $50.44 and its 200 day moving average price is $48.38. Integra LifeSciences Holdings Corporation has a 12-month low of $37.71 and a 12-month high of $56.42. The company has a market cap of $4.05 billion, a P/E ratio of 63.32 and a beta of 0.73.

In related news, Director Donald E. Morel, Jr. acquired 10,000 shares of Integra LifeSciences Holdings Corporation stock in a transaction that occurred on Friday, August 4th. The stock was bought at an average price of $49.25 per share, with a total value of $492,500.00. Following the transaction, the director now directly owns 29,612 shares in the company, valued at $1,458,391. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Donald E. Morel, Jr. acquired 2,500 shares of Integra LifeSciences Holdings Corporation stock in a transaction that occurred on Thursday, August 3rd. The shares were bought at an average cost of $49.29 per share, with a total value of $123,225.00. Following the transaction, the director now owns 29,612 shares in the company, valued at $1,459,575.48. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 17,550 shares of company stock valued at $864,842. 21.50% of the stock is owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of IART. Bank of Montreal Can increased its holdings in shares of Integra LifeSciences Holdings Corporation by 89.0% in the 1st quarter. Bank of Montreal Can now owns 8,642 shares of the life sciences company’s stock worth $364,000 after purchasing an additional 4,069 shares in the last quarter. Profund Advisors LLC increased its holdings in shares of Integra LifeSciences Holdings Corporation by 65.5% in the 1st quarter. Profund Advisors LLC now owns 11,349 shares of the life sciences company’s stock worth $478,000 after purchasing an additional 4,492 shares in the last quarter. ProShare Advisors LLC increased its holdings in shares of Integra LifeSciences Holdings Corporation by 51.2% in the 1st quarter. ProShare Advisors LLC now owns 8,350 shares of the life sciences company’s stock worth $352,000 after purchasing an additional 2,829 shares in the last quarter. Strs Ohio increased its holdings in shares of Integra LifeSciences Holdings Corporation by 100.0% in the 1st quarter. Strs Ohio now owns 4,800 shares of the life sciences company’s stock worth $202,000 after purchasing an additional 2,400 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in shares of Integra LifeSciences Holdings Corporation by 71.1% in the 1st quarter. Russell Investments Group Ltd. now owns 244,924 shares of the life sciences company’s stock worth $10,318,000 after purchasing an additional 101,744 shares in the last quarter. 85.28% of the stock is owned by institutional investors.

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Get a free copy of the Zacks research report on Integra LifeSciences Holdings Corporation (IART)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.